CA2400638A1 - 7 proteines humaines ovariennes et proteines associees au cancer des ovaires - Google Patents

7 proteines humaines ovariennes et proteines associees au cancer des ovaires Download PDF

Info

Publication number
CA2400638A1
CA2400638A1 CA002400638A CA2400638A CA2400638A1 CA 2400638 A1 CA2400638 A1 CA 2400638A1 CA 002400638 A CA002400638 A CA 002400638A CA 2400638 A CA2400638 A CA 2400638A CA 2400638 A1 CA2400638 A1 CA 2400638A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
polypeptides
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400638A
Other languages
English (en)
Inventor
Charles E. Birse
Craig A. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400638A1 publication Critical patent/CA2400638A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries

Abstract

L'invention concerne de nouveaux polynucléotides ovariens ou associés au cancer des ovaires et les polypeptides codés par ces polynucléotides désignés collectivement <= antigènes du cancer des ovaires >=, et l'utilisation de ces antigènes ovariens afin de détecter des troubles du système reproductif, en particulier, la présence d'un cancer des ovaires ou de métastases du cancer des ovaires. Elle concerne des antigènes du cancer des ovaires, ainsi que des vecteurs, des cellules hôtes, des anticorps dirigés contre des antigènes du cancer des ovaires, les procédés de recombinaison et les procédés de synthèse servant à les préparer. Elle concerne également des procédés diagnostiques servant à détecter, traiter, prévenir et/ou pronostiquer des troubles associés aux ovaires, y compris le cancer des ovaires, et des procédés thérapeutiques servant à traiter ces troubles. Elle concerne, de plus, des procédés de criblage servant à identifier des agonistes et des antagonistes de ces antigènes du cancer des ovaires. Elle concerne également l'inhibition de la production et du fonctionnement de ces polypeptides.
CA002400638A 2000-03-17 2001-03-16 7 proteines humaines ovariennes et proteines associees au cancer des ovaires Abandoned CA2400638A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
PCT/US2001/008585 WO2001070804A1 (fr) 2000-03-17 2001-03-16 7 proteines humaines ovariennes et proteines associees au cancer des ovaires

Publications (1)

Publication Number Publication Date
CA2400638A1 true CA2400638A1 (fr) 2001-09-27

Family

ID=26885755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400638A Abandoned CA2400638A1 (fr) 2000-03-17 2001-03-16 7 proteines humaines ovariennes et proteines associees au cancer des ovaires

Country Status (5)

Country Link
EP (1) EP1268541A1 (fr)
JP (1) JP2003527851A (fr)
AU (1) AU2001252917A1 (fr)
CA (1) CA2400638A1 (fr)
WO (1) WO2001070804A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
MXPA03009510A (es) * 2001-04-17 2005-04-29 Univ Arkansas Secuencias de repeticion del gen ca125 y su uso para intervenciones de diagnosticos y terapeuticas.
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
EP2298806A1 (fr) 2002-10-16 2011-03-23 Purdue Pharma L.P. Anticorps se fixant sur des polypeptides CA 125/0722P associés à des cellules et leurs procédés d'utilisation
CN101444621B (zh) * 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
EP2056110A1 (fr) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarqueur pour prédire une réponse à un traitement par un anti-TNF-alpha
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN114190990A (zh) 2014-08-12 2022-03-18 新生代吉恩公司 用于基于收集的体液而监测健康的系统和方法
EP3442706A4 (fr) 2016-04-13 2020-02-19 NextGen Jane, Inc. Dispositifs, systèmes et procédés de collecte et de conservation d'échantillon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor

Also Published As

Publication number Publication date
EP1268541A1 (fr) 2003-01-02
AU2001252917A1 (en) 2001-10-03
JP2003527851A (ja) 2003-09-24
WO2001070804A1 (fr) 2001-09-27

Similar Documents

Publication Publication Date Title
US7368531B2 (en) Human secreted proteins
US7968689B2 (en) Antibodies to HSDEK49 polypeptides
US20020081659A1 (en) Nucleic acids, proteins and antibodies
US20030059875A1 (en) Nucleic acids, proteins, and antibodies
US20030040617A9 (en) Nucleic acids, proteins and antibodies
US20020039764A1 (en) Nucleic, acids, proteins, and antibodies
CA2392757A1 (fr) Acides nucleiques, proteines et anticorps
US20030064072A9 (en) Nucleic acids, proteins and antibodies
CA2395525A1 (fr) Polynucleotides, polypeptides, et anticorps de transferrine
CA2395811A1 (fr) Acides nucleiques, proteines, et anticorps
CA2403508A1 (fr) Polynucleotides, polypeptides et anticorps matriciels extracellulaires
US20020151681A1 (en) Nucleic acids, proteins and antibodies
CA2394753A1 (fr) Polynucleotides et polypeptides de la protein thyrosine phosphatase humaine, et anticorps
CA2398227A1 (fr) 17 proteines secretees humaines
CA2400638A1 (fr) 7 proteines humaines ovariennes et proteines associees au cancer des ovaires
US20060073561A1 (en) 157 human secreted proteins
US20030054379A1 (en) Nucleic acids, proteins, and antibodies
CA2391594A1 (fr) Anticorps, polypeptides et polynucleotides contenant un domaine dit en feuille de trefle
CA2386641A1 (fr) 32 proteines humaines secretees
CA2399921A1 (fr) Polynucleotides et polypeptides de la proteine tyrosine phosphatase, et anticorps
US20050214786A1 (en) 26 human secreted proteins
US20040010121A1 (en) 7 Human ovarian and ovarian cancer associated proteins
CA2418676A1 (fr) 21 proteines humaines secretees
US20020164692A1 (en) Immune system-related polynucleotides, polypeptides, and antibodies
CA2423559A1 (fr) Proteines secretees humaines 22

Legal Events

Date Code Title Description
FZDE Discontinued